Tuberculosis claims the lives of over a million people every year. Efforts to control the disease are significantly hindered by inadequate treatment options and the absence of an effective vaccine. Faced with these challenges, what strategies can we pursue to develop new treatments and preventive measures to combat this ongoing pandemic?
Join Dr Eric Rubin, Editor-in-Chief of the New England Journal of Medicine, as he shares insights from his detailed lab research on tuberculosis.
Eric Rubin is Editor-in-Chief of the New England Journal of Medicine. He earned an AB degree from Harvard College and MD and PhD degrees from Tufts University, did clinical training at the Massachusetts General Hospital and postdoctoral work at Harvard Medical School. He is an Adjunct Professor at the Harvard TH Chan School of Public Health where his lab studies tuberculosis. Eric also practices infectious disease at the Brigham and Women’s Hospital and is a Professor of Medicine at Harvard Medical School. He is a member of the American Academy of Microbiology, the American Association of Physicians and the National Academy of Medicine.
Professor Anthony Kelleher is the Director of the Kirby Institute at UNSW. He is a leading HIV clinical scientist who has been involved with every HIV vaccine trial conducted in Australia, and multiple phase I-IV clinical trials, particularly those involving patients with primary infection. He is currently working on mapping the HIV reservoir and developing a novel “block and lock” approach towards clinical application, and is also leading major projects investigating antibody therapies to treat COVID-19. Professor Kelleher has been Head of the Immunovirology and Pathogenesis Program at the Kirby Institute since 2005. He is also a clinical academic at St Vincent’s Hospital, Sydney, responsible for clinical care of patients with HIV infection and autoimmune diseases as well as oversight of the NSW State HIV Reference laboratory.
